GWM
CPRX

Gilpin Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Gilpin Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$570 Buy
23
+15
+188% +$357 ﹤0.01% 575
2025
Q4 		$187 Buy
+8
New +$178 ﹤0.01% 676

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Gilpin Wealth Management's CPRX Position: Q1 2026 in Review

Gilpin Wealth Management increased its Catalyst Pharmaceutical (CPRX) stake by 188% in Q1 2026, buying an estimated $357 and bringing the position to 23 shares worth $570. The position accounts for ﹤0.01% of the portfolio, ranked #575.

Gilpin Wealth Management first reported a position in CPRX in Q4 2025 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Gilpin Wealth Management held 23 shares of Catalyst Pharmaceutical worth $570 as of Q1 2026.
  • Gilpin Wealth Management bought 15 Catalyst Pharmaceutical shares in Q1 2026, an estimated $357.
  • Catalyst Pharmaceutical made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q1 2026, its #575 holding.
  • Gilpin Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Gilpin Wealth Management's 13F filing for Q1 2026, filed 21 Apr 2026.